Endo International: Difference between revisions

Latest revision as of 04:30, 9 January 2025

==Overview==

Endo International is a global specialty pharmaceutical company that develops, manufactures, and distributes a broad range of branded and generic pharmaceutical products. The company is headquartered in Dublin, Ireland, and has operations in various countries around the world.

History[edit]

Endo International was founded in 1997 as a result of a management buyout from DuPont Merck. The company initially focused on pain management and expanded its portfolio through strategic acquisitions and product development. Over the years, Endo has acquired several companies, including Paladin Labs, Par Pharmaceutical, and Auxilium Pharmaceuticals, to enhance its product offerings and market presence.

Business Segments[edit]

Endo International operates through several business segments:

Branded Pharmaceuticals[edit]

This segment includes the development and marketing of branded prescription products. Key therapeutic areas include pain management, urology, and endocrinology.

Sterile Injectables[edit]

Endo's sterile injectables segment focuses on the production and distribution of injectable products, including generic and branded formulations.

Generic Pharmaceuticals[edit]

The generic pharmaceuticals segment involves the development, manufacturing, and marketing of generic drugs. This segment was significantly expanded through the acquisition of Par Pharmaceutical.

Products[edit]

Endo International offers a wide range of products across various therapeutic areas. Some of the notable products include:

[[Opana ER - An extended-release opioid analgesic for pain management.
[[Xiaflex - A collagenase clostridium histolyticum injection for the treatment of Dupuytren's contracture and Peyronie's disease.
[[Vasostrict - A vasopressin injection used to increase blood pressure in adults with vasodilatory shock.

Controversies[edit]

Endo International has faced several controversies, particularly related to its opioid products. The company has been involved in litigation concerning the marketing and distribution of opioid medications, which have been linked to the opioid epidemic in the United States.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S. based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system<br>[[Category:Drugs]]<br>
+[[File:Endo_Pharmaceuticals_Logo.png|thumb]]==Overview==
-{{stb}}
-{{short-articles-ni}}
+'''Endo International''' is a global specialty pharmaceutical company that develops, manufactures, and distributes a broad range of branded and generic pharmaceutical products. The company is headquartered in Dublin, Ireland, and has operations in various countries around the world.
+==History==
+Endo International was founded in 1997 as a result of a management buyout from DuPont Merck. The company initially focused on pain management and expanded its portfolio through strategic acquisitions and product development. Over the years, Endo has acquired several companies, including [[Paladin Labs]], [[Par Pharmaceutical]], and [[Auxilium Pharmaceuticals]], to enhance its product offerings and market presence.
+==Business Segments==
+Endo International operates through several business segments:
+===Branded Pharmaceuticals===
+This segment includes the development and marketing of branded prescription products. Key therapeutic areas include pain management, urology, and endocrinology.
+===Sterile Injectables===
+Endo's sterile injectables segment focuses on the production and distribution of injectable products, including generic and branded formulations.
+===Generic Pharmaceuticals===
+The generic pharmaceuticals segment involves the development, manufacturing, and marketing of generic drugs. This segment was significantly expanded through the acquisition of Par Pharmaceutical.
+==Products==
+Endo International offers a wide range of products across various therapeutic areas. Some of the notable products include:
+* '''[[Opana ER''' - An extended-release opioid analgesic for pain management.
+* '''[[Xiaflex''' - A collagenase clostridium histolyticum injection for the treatment of Dupuytren's contracture and Peyronie's disease.
+* '''[[Vasostrict''' - A vasopressin injection used to increase blood pressure in adults with vasodilatory shock.
+==Controversies==
+Endo International has faced several controversies, particularly related to its opioid products. The company has been involved in litigation concerning the marketing and distribution of opioid medications, which have been linked to the opioid epidemic in the United States.
+==Related Pages==
+* [[Pharmaceutical industry]]
+* [[Opioid epidemic]]
+* [[Generic drug]]
+* [[Pain management]]
+{{Pharmaceutical companies}}
+[[Category:Pharmaceutical companies of Ireland]]
+[[Category:Companies established in 1997]]
+[[Category:Specialty pharmaceutical companies]]